Join health plan executives for an in-depth discussion about managing the cost, utilization, quality and value of genetic testing.

Genetic Testing Management for Health Plans 
Managing cost, quality and value in a rapidly evolving market. 

December 15th, 2016
Online event (recording)

Advances in science and technology and the rise of personalized medicine are driving rapid growth in genetic testing. Spend for many health plans is rising more than 25% per year.

Managing this space, which spans across oncology, pharmacology, rare disease, women’s health and many other clinical areas, is uniquely challenging. There are more than 65,000 genetic testing products on the market, and 8-10 new products enter each day. Yet, fewer than 200 codes exist to bill these tests, and clinical utility data is often sparse and inconclusive.  As a result, health plans face the overlapping challenges of establishing medical policies, contracting with laboratories, paying claims correctly, and ultimately, serving their members, all in the presence of limited data and continual change.

In this webinar, leading executives discuss their perspectives on the present and future of genetic testing, and how their organizations are managing it.

Participants in the webinar will learn:

  1. Key reasons genetic testing is an area of focus for leading health plans;
  2. Perspectives on assessing clinical utility, establishing medical policy – and ultimately, measuring value – when data is scarce;
  3. Practical lessons from experience implementing utilization management programs; and
  4. Advice specifically for leaders who are just beginning to address genetic testing management for their health plan.

Who should listen:

  • Medical directors and other clinicians at health plans charged with assessing clinical utility and establishing medical payment policies;
  • Health plan contracting professionals faced with the challenge of contracting with genetic testing laboratories;
  • Claims operations, cost management and payment integrity professionals seeking to ensure genetic testing claims are paid fairly and accurately; and
  • Health care providers and laboratories seeking insight into health insurers’ perspectives on genetic testing.



Lee N. Newcomer, MD, MHA
Senior Vice President, Oncology and Genetics

Henry Garlich
Director of Enhanced Clinical Programs

Cliff Goodman, PhD (moderator)
Senior Vice President and Director, Center for Comparative Effectiveness Research